April 15, 2025 09:39 AM EDT
People
R&D

Mur­al On­col­o­gy ends clin­i­cal de­vel­op­ment, lays off most work­ers

Kyle LaHucik

Senior Reporter

Boston and Dublin biotech Mur­al On­col­o­gy is lay­ing off near­ly all of its em­ploy­ees and end­ing clin­i­cal de­vel­op­ment of its IL-2 drug nem­valeukin al­fa. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

TRENDING NOW

Sanofi to pay $125M up­front for two im­munol­o­gy drugs from lit­tle-known biotech

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

Nether­lands pours $1.5B in­to biotech in pur­suit of glob­al lead­er­ship am­bi­tions

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times